Biosimilar White Papers

  1. Leading The Edge Of Innovation Into Cell Culture Media Quality 12/16/2020

    In this white paper, we highlight the breadth of programs implemented across our organization to safeguard the quality of the cell culture media that are used in our customer processes.

  2. Not Everyone Loves Surprises: Know Your ADC’s Critical Quality Attributes 2/21/2020

    Combatting the challenges of developing and manufacturing ADCs requires robust product characterization throughout all phases of development.

  3. End Of End Point Assays: SPR Analytics In Vaccine Design, Development 2/18/2021

    Discover how SPR can be used to accelerate vaccine discovery and development by helping overcome analytical challenges that have plagued the industry for decades.

  4. How Buffer pH And NaCl Affect Size Exclusion Chromatography 4/22/2020

    Using a design of experiments approach, this study describes the effect of buffer pH and NaCl concentration on proteins purified by size exclusion chromatography.

  5. Pairing Data Connectivity, Automation Ease Tech Transfer/Scale-Up 2/11/2020

    In biopharma, process data is used in many ways throughout process development and production phases. This article outlines how connectivity and comprehensive automation ease tech transfer and scale up.

  6. Rapid Biosafety Testing Enables The Future Of Manufacturing 7/15/2020

    This whitepaper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing that are more aligned with manufacturing trends.

  7. Strategies For Upstream Intensification 8/14/2020

    Upstream intensification is one strategy that will enable the Facility Of The Future by significantly driving down costs through an increase in volumetric productivity. Read the white paper to learn more!

  8. Embedding Your Drug Strategy Within A Solid Foundation For Success 3/24/2020

    This white paper looks at the set of trends influencing pharmaceutical development and manufacturing strategy today, and how these drivers are influencing new business models with outsourced partners. 

  9. LV Scale-Up Workflow In Single-Use Bioreactors For GMP Compliance 11/8/2019

    Cost-effective manufacturing of lentiviral vectors (LV) at commercial scales has proven difficult and remains a pressing issue for the marketing of therapies that depend on their application.

  10. Single-Use Platforms Accelerate Viral Vaccine Development, Manufacturing 10/31/2019

    Analysts predict the vaccine market could grow at as much as 10.3 percent through 2024 (CAGR). Single-use platforms might be pivotal to meeting that demand.